203 related articles for article (PubMed ID: 29673076)
1. Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.
Greenland JR; Chong T; Wang AS; Martinez E; Shrestha P; Kukreja J; Hays SR; Golden JA; Singer JP; Tang Q
Am J Transplant; 2018 Aug; 18(8):2043-2049. PubMed ID: 29673076
[TBL] [Abstract][Full Text] [Related]
2. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival.
Gallagher HM; Sarwar G; Tse T; Sladden TM; Hii E; Yerkovich ST; Hopkins PM; Chambers DC
J Heart Lung Transplant; 2015 Nov; 34(11):1442-8. PubMed ID: 26186804
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of inhaled nanoparticle tacrolimus in preventing rejection in an orthotopic rat lung transplant model.
Das NA; Peters JI; Simmons JD; Wang Y; O'Donnell KP; DeArmond DT; Coalson JJ; Brooks EG; Johnson SB
J Thorac Cardiovasc Surg; 2017 Dec; 154(6):2144-2151.e1. PubMed ID: 28942970
[TBL] [Abstract][Full Text] [Related]
4. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.
Dugast E; Soulillou JP; Foucher Y; Papuchon E; Guerif P; Paul C; Riochet D; Chesneau M; Cesbron A; Renaudin K; Dantal J; Giral M; Brouard S
Am J Transplant; 2016 Nov; 16(11):3255-3261. PubMed ID: 27367750
[TBL] [Abstract][Full Text] [Related]
5. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
6. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.
Chhabra D; Alvarado A; Dalal P; Leventhal J; Wang C; Sustento-Reodica N; Najafian N; Skaro A; Levitsky J; Mas V; Gallon L
Am J Transplant; 2013 Nov; 13(11):2902-11. PubMed ID: 24007570
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics.
Israni AK; Riad SM; Leduc R; Oetting WS; Guan W; Schladt D; Matas AJ; Jacobson PA;
Transpl Int; 2013 Oct; 26(10):982-9. PubMed ID: 23879408
[TBL] [Abstract][Full Text] [Related]
8. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
[TBL] [Abstract][Full Text] [Related]
10. Preoperative introduction and maintenance immunosuppression therapy of oral-only tacrolimus, mycophenolate mofetil and steroids reduce acute rejection episodes after lung transplantation.
Bittner HB; Barten MJ; Binner C; Lehmann S; Garbade J; Hammerschmidt S; Wirtz H; Mohr FW
Eur J Cardiothorac Surg; 2010 Sep; 38(3):268-76. PubMed ID: 20304665
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study.
Sommerer C; Brunet M; Budde K; Millán O; Guirado Perich L; Glander P; Meuer S; Zeier M; Giese T
Br J Clin Pharmacol; 2021 Oct; 87(10):3851-3862. PubMed ID: 33620734
[TBL] [Abstract][Full Text] [Related]
12. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
13. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
14. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
15. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
16. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients.
Santos T; Santos L; Macário F; Romãozinho C; Alves R; Campos M; Mota A
Transplant Proc; 2015 May; 47(4):906-10. PubMed ID: 26036483
[TBL] [Abstract][Full Text] [Related]
17. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
19. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
